Oral · GLP-1 agonist
Danuglipron
20 trials in this molecule. Source: ClinicalTrials.gov, as of July 1, 2026.
Trials
20
Active
0
Recruiting
0
Completed
19
Sites
153
Countries
12
Endpoints
402
Composite endpoints
13
Distinct sites and countries across this molecule's trials. A site running several of its trials counts once, matching the map.
Development
Where the program stands
Trials by phase
Phase 1
17
Phase 2
3
Trials by status
Completed
19
Terminated
1
Evidence coverage
What this asset has been measured on
Endpoints grouped into outcome categories, ranked by how often they are measured across this asset's trials.
Safety / tolerability / PK
287
Weight & body composition
60
Glycemic / diabetes
45
Patient-reported / QoL
9
Cardiometabolic biomarkers
1
Most-measured metrics
Top 20 metrics across this asset's endpoints
AUC₀–∞Safety/PK
38
CmaxSafety/PK
28
Treatment-emergent AEs (any)Safety/PK
23
Body weight, absolute change (kg)Weight
22
HbA1c, changeGlycemic
14
Fasting glucose, changeGlycemic
14
TmaxSafety/PK
9
Half-lifeSafety/PK
7
Body weight, % changeWeight
6
Discontinuation due to AESafety/PK
3
≥5% weight-loss respondersWeight
2
Waist circumference, changeWeight
2
Plasma concentration (steady state)Safety/PK
1
HbA1c <7.0% achievementGlycemic
1
Trials
Programs for this asset
Every trial for this molecule, with the same search, filters, and sort as the Trials tab.
⌘K
20 of 20